Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic ... Previous studies have focused on the improvements in β-cell function, while the inhibition of α-cell secretion ...

"Palatin concludes Phase II trial of combination therapy for obesity" was originally created and published by Clinical Trials ...

Endometrial cancer (EC) ranks as the second most prevalent gynecologic malignancy globally, with approximately 189,000 new ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

Neurons in the brains of mice tell them to stop eating when they’ve had enough food – and since people probably have the same ...